Diabetes Complications: Retinopathy, Nephropathy, Neuropathy

Table of Contents

  1. The Big Three — Why They Cluster
  2. Retinopathy — Saving Your Vision
  3. Retinopathy Screening Cadence
  4. Retinopathy Treatments
  5. Nephropathy — Protecting Your Kidneys
  6. Nephropathy Screening — UACR and eGFR
  7. Nephropathy Treatments — The Four Pillars
  8. Neuropathy — Nerves Under Glucose Attack
  9. Autonomic and Focal Neuropathies
  10. Neuropathy Screening
  11. Neuropathy Treatments
  12. Other Complications — Feet, Bones, Brain, Ears
  13. Intensive Control Caveats
  14. A Word on Metformin and B12
  15. Key Research Papers
  16. Research Papers
  17. Connections

The Big Three — Why They Cluster

Diabetes complications are often called "micro" and "macro" vascular. The microvascular trio — retinopathy, nephropathy, neuropathy — all start in the same place: the smallest blood vessels in your body. High glucose damages the inner lining of capillaries, thickens their basement membranes, and leaks fluid into tissues that depend on pristine microcirculation. The retina, the kidney glomerulus, and the nerve sheath are unusually vulnerable because each of them is fed by delicate capillary beds with almost no collateral blood supply. When those capillaries go, the organ goes.

The good news: all three complications share the same levers. Tight glucose control, tight blood pressure control, and a handful of specific drug classes slow or halt every one of them. The landmark DCCT trial in type 1 diabetes and the UKPDS trial in type 2 diabetes both showed that each 1% drop in A1c cuts microvascular complication risk by roughly 35–40%. Those benefits compound over decades — a concept called metabolic memory. What you do in the first ten years of your diagnosis keeps paying dividends thirty years later.

This article walks through each complication: what it is, how to screen for it, and how modern medicine treats it. Screening is the single most powerful thing you can do, because every one of these diseases is silent in the stage where it is most reversible.

Retinopathy — Saving Your Vision

Diabetic retinopathy is the leading cause of blindness in working-age adults in the developed world. It progresses through predictable stages:

Overlapping all of these stages is diabetic macular edema (DME) — fluid leaking into the central retina (the macula), blurring reading vision. Macular edema can occur at any NPDR or PDR stage, and it is now the most common cause of vision loss in diabetes, because we catch PDR earlier than we used to.

Retinopathy Screening Cadence

The American Diabetes Association and the American Academy of Ophthalmology agree on the cadence:

How it is screened. A dilated fundus exam by an ophthalmologist or optometrist remains the gold standard. Fundus photography is increasingly used in primary care — a retinal camera takes high-resolution photos, and either a specialist or an AI reads them. In 2018 the FDA approved IDx-DR, the first autonomous AI medical device ever cleared in any specialty, which reads retinal photos and issues a "refer" or "rescreen in 12 months" result without a human specialist. If your primary care clinic has a retinal camera, the exam takes 10 minutes and does not require pupil dilation. Optical coherence tomography (OCT) is a separate test, performed by eye specialists, that shows cross-sectional layers of the retina; it is the standard for detecting and monitoring macular edema.

Retinopathy Treatments

A generation ago, laser was all we had. Now the toolkit is much deeper.

Anti-VEGF intravitreal injections. The backbone of modern treatment. A tiny needle delivers an anti-VEGF drug directly into the vitreous gel, typically monthly at first and then tapered. The three workhorses are ranibizumab (Lucentis), aflibercept (Eylea), and the newer faricimab (Vabysmo), which blocks both VEGF-A and angiopoietin-2 and can often be dosed every 3–4 months. Bevacizumab (Avastin) is used off-label at much lower cost and works nearly as well for most patients. Anti-VEGF injections both treat macular edema and shrink proliferative neovessels.

Laser photocoagulation. Still the standard for high-risk PDR when injections are not enough. Panretinal photocoagulation (PRP) uses hundreds of laser burns on the peripheral retina to reduce the drive for neovascular growth, trading peripheral vision for preservation of the central vision. Focal/grid laser treats isolated leaking microaneurysms in the macula.

Steroid implants. For macular edema that resists anti-VEGF, sustained-release dexamethasone implants (Ozurdex) or the fluocinolone implant (Iluvien) deliver months of anti-inflammatory effect inside the eye.

Vitrectomy. Surgical removal of the vitreous gel, reserved for vitreous hemorrhage that does not clear or for traction retinal detachment. Modern small-gauge vitrectomy is outpatient and dramatically safer than it was twenty years ago.

Fenofibrate. A surprise from the FIELD and ACCORD-Eye trials: this generic lipid drug, originally prescribed for triglycerides, slowed retinopathy progression by roughly 40% independent of its cholesterol effect. Ask your endocrinologist whether it fits your profile, especially if you also have mild hypertriglyceridemia.

If you are told you need injections, do not panic. The needle is small, the eye is numbed, and most patients describe the experience as strange but not painful. The injections preserve vision that no other treatment can rescue. Refusing them because of needle fear is the single most common preventable path to diabetic blindness.

Nephropathy — Protecting Your Kidneys

Diabetic kidney disease (DKD) is now the number-one cause of end-stage renal disease in the United States, accounting for about 45% of new dialysis starts. It unfolds over years and is almost entirely silent until late.

The classical progression:

  1. Hyperfiltration. The kidneys actually work harder early on; eGFR can be above normal.
  2. Microalbuminuria. Small amounts of albumin start leaking into urine — 30–300 mg/g urinary albumin-to-creatinine ratio (UACR). This is the earliest clinically detectable sign, and it usually appears years before creatinine rises.
  3. Macroalbuminuria. UACR climbs above 300 mg/g. Protein leak becomes detectable on a standard dipstick.
  4. Declining eGFR. Glomerular filtration rate falls, creatinine climbs, and the kidneys can no longer compensate.
  5. End-stage renal disease. eGFR below 15 mL/min/1.73m². Dialysis or transplant required.

The take-home: the first sign of diabetic kidney injury is almost always an albumin leak, not a creatinine rise. If you wait for your creatinine to climb, you have already lost half of your nephron reserve. That is why screening is so essential, and why it rests on the UACR, not the basic metabolic panel alone.

Nephropathy Screening — UACR and eGFR

What to order. Two tests, annually:

When to start. Type 1 diabetes: 5 years after diagnosis, then annually. Type 2 diabetes: at diagnosis, then annually. Pregnancy: early, and then per obstetrician guidance.

Interpreting results. A single elevated UACR does not confirm DKD — exercise, fever, menstruation, or a urinary tract infection can all transiently raise it. Confirm with two out of three positive samples over 3–6 months. Once confirmed, microalbuminuria is the threshold at which drug therapy should begin (see the next section), whether or not your blood pressure is high and whether or not your creatinine has moved.

Nephropathy Treatments — The Four Pillars

Modern DKD treatment rests on four complementary drug classes plus blood pressure and protein targets. Each one independently slows kidney function decline. Used together, they can often stabilize kidney function for years.

1. ACE inhibitors or ARBs. First-line for any patient with albuminuria, regardless of blood pressure. These drugs relax the efferent arteriole of the glomerulus and lower intraglomerular pressure — a pure kidney-protective effect separate from their blood-pressure benefit. Lisinopril, ramipril, enalapril (ACEi), losartan, valsartan, telmisartan (ARB). Do not use them together — combined ACEi + ARB increases harm without benefit.

2. SGLT2 inhibitors. The single biggest advance in DKD in a generation. Empagliflozin, dapagliflozin, and canagliflozin reduce glomerular hyperfiltration, lower intraglomerular pressure, and protect kidneys through mechanisms independent of glucose lowering. Three trials — CREDENCE, DAPA-CKD, and EMPA-KIDNEY — established that these drugs slow kidney decline in DKD and in non-diabetic kidney disease alike. SGLT2 inhibitors are now FDA-approved for chronic kidney disease regardless of diabetes status. See the sibling article on cardio-renal protection for the full trial data.

3. Non-steroidal mineralocorticoid receptor antagonist — finerenone (Kerendia). A newer class. The FIDELIO-DKD and FIGARO-DKD trials showed finerenone reduces both kidney and cardiovascular events in patients with DKD and type 2 diabetes already on maximal ACEi/ARB therapy. It is layered on top of, not instead of, the renin-angiotensin blocker. Watch serum potassium; finerenone can raise it.

4. GLP-1 receptor agonists. Semaglutide and similar drugs were long suspected to help kidneys, and the FLOW trial in 2024 confirmed renal benefit in type 2 DKD. Weight loss, blood pressure reduction, and direct renal anti-inflammatory effects appear to contribute.

Blood pressure target: under 130/80 mm Hg. Lower is not necessarily better — aggressive targets below 120/70 can precipitate falls and acute kidney injury in older patients.

Dietary protein: around 0.8 g/kg body weight per day. This is a moderation target, not a low-protein diet. Going substantially below 0.8 g/kg risks muscle loss and malnutrition without additional kidney benefit. A 70 kg adult eats roughly 56 g of protein a day, which is two modest chicken-breast portions or an equivalent plant-based mix.

Nephrology referral. When eGFR drops below 30 mL/min/1.73m², or when it is falling rapidly (more than 5 mL/min per year), refer to a nephrologist. Early referral cuts the risk of a chaotic dialysis start.

Neuropathy — Nerves Under Glucose Attack

Up to half of all people with long-standing diabetes develop some form of neuropathy. The most common by far is distal symmetric polyneuropathy — the classic "stocking-glove" pattern that begins in the toes and creeps upward, usually symmetrically, over years.

Symptoms progress in a predictable order:

A painful variant, painful diabetic neuropathy (PDN), affects about a third of patients with polyneuropathy. The pain is often described as burning, stabbing, electric, or "walking on broken glass," and it characteristically worsens at night and with inactivity. Tesfaye and colleagues' 2010 Toronto consensus paper remains the definitive reference on classification and treatment.

Small-fiber neuropathy is a particularly important subtype. Only the tiniest unmyelinated C-fibers are affected; standard nerve conduction studies are normal, and diagnosis requires a skin biopsy showing reduced intraepidermal nerve fiber density. Small-fiber neuropathy overlaps substantially with fibromyalgia, with POTS, and with Long-COVID-like autonomic syndromes — patients can spend years being told their symptoms are psychological before the diagnosis is made. See the small-fiber neuropathy overlap article for more.

Autonomic and Focal Neuropathies

Autonomic neuropathy affects the nerves that run your internal organs. It is under-diagnosed because symptoms are vague and rarely linked to diabetes by patients or primary care teams.

Focal neuropathies affect a single nerve at a time, often abruptly.

Neuropathy Screening

Annual foot exam in a primary care or endocrine clinic, using four quick bedside tools:

When to start. Type 1 diabetes: 5 years after diagnosis, then annually. Type 2 diabetes: at diagnosis, then annually. Any patient with symptoms should be examined immediately regardless of duration.

For suspected autonomic disease, order targeted testing: tilt-table testing for orthostatic intolerance, gastric emptying scintigraphy for gastroparesis, QSART or skin biopsy for small-fiber and sudomotor disease.

Neuropathy Treatments

The uncomfortable truth: no drug currently reverses diabetic nerve damage. What we have are drugs that dampen pain and slow progression. The best-proven disease-modifier is still tight glycemic control.

First-line for painful neuropathy (ADA-preferred):

Most patients need to try two or three of these before landing on a tolerable combination. All have meaningful side effects — sedation, weight gain, dry mouth, or edema — so start low and go slow.

Newer options. Capsaicin 8% patch (Qutenza) is applied for 30–60 minutes in a clinic and can provide 3 months of pain relief by depleting pain-fiber neurotransmitters. Spinal cord stimulation is now FDA-approved for refractory painful diabetic neuropathy and produces life-changing relief in carefully selected patients whose pain has not responded to medications.

Topical agents. Lidocaine 5% patches, capsaicin cream, and compounded amitriptyline/ketamine creams offer modest benefit for focal pain and spare you some systemic side effects.

Opioids are not first-line and should be avoided long-term. They rarely help neuropathic pain at tolerable doses and carry addiction risk.

Alpha-lipoic acid at 600 mg daily has modest evidence in European trials; it is inexpensive, well-tolerated, and reasonable to try. Benfotiamine (a fat-soluble thiamine analogue) has weaker evidence.

Foot-care infrastructure matters as much as pills: well-fitted shoes, daily foot inspection (use a mirror), immediate attention to any blister or crack, and regular podiatry visits. Diabetic foot ulcers are the leading non-traumatic cause of lower-limb amputation in the developed world, and nearly all begin as a silent insensate injury.

Other Complications — Feet, Bones, Brain, Ears

Beyond the classic triad, diabetes touches nearly every organ system. The ones worth knowing about:

Intensive Control Caveats

The DCCT and UKPDS story — lower A1c, fewer complications — is true but not universal. The ACCORD trial in 2008 enrolled patients with long-standing type 2 diabetes and high cardiovascular risk, randomizing them to an A1c target below 6.0% versus standard 7.0–7.9%. The intensive arm had more deaths, and the trial was stopped early. Subsequent analyses suggest the excess mortality was driven by severe hypoglycemia and by how aggressively the target was pursued, not by low A1c per se.

The lesson: individualize your target. A 35-year-old with new type 1 diabetes, no complications, and no hypoglycemia unawareness should probably aim for an A1c of 6.5% or lower. A 75-year-old with 20 years of type 2 diabetes, coronary disease, and a history of passing out from low sugar should aim for 7.5–8.0% and prioritize avoiding hypoglycemia. Tight control is a gift in the first decade of diabetes and a trap in the fourth. See the sibling article on hypoglycemia awareness and prevention for why severe lows count as a complication in their own right.

A Word on Metformin and B12

Metformin interferes with B12 absorption in the terminal ileum. Patients who have been on metformin longer than about 4 years have a meaningfully higher rate of B12 deficiency, and the symptoms — tingling, numbness, fatigue — are easy to mistake for diabetic neuropathy itself. Check a serum B12 level (or methylmalonic acid if B12 is borderline) at least every 2–3 years on long-term metformin, and sooner if neuropathic symptoms appear. Replacement is cheap, oral, and effective; missing the diagnosis means treating a reversible deficiency as if it were permanent nerve damage.

Key Research Papers

Research Papers

For further reading, the following PubMed topic searches return current peer-reviewed work on each complication and its treatment:

  1. Diabetic retinopathy and anti-VEGF therapy
  2. Diabetic macular edema and faricimab
  3. Diabetic retinopathy AI screening
  4. Diabetic nephropathy and SGLT2 inhibitors
  5. Finerenone FIDELIO and FIGARO trials
  6. Semaglutide FLOW trial renal outcomes
  7. Painful diabetic neuropathy treatment
  8. Cardiovascular autonomic neuropathy in diabetes
  9. Small-fiber neuropathy and skin biopsy
  10. ACCORD intensive glucose control and mortality
  11. Metformin and vitamin B12 deficiency

Connections

Back to Table of Contents